Background: About 15%-20% of colorectal cancers (CRCs) are familial. While a fraction of these arise in the context of hereditary syndromes, the causes underlying the majority of familial CRCs are not yet understood.
Introduction
Presence of a positive family history is a well-established risk factor for colorectal carcinoma (CRC) [1] [2] [3] . Several conditions associated with CRC predisposition are known, and the causative genes have been cloned. The most common hereditary CRC syndromes are familial adenomatous polyposis (FAP) and Lynch syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), which are caused by mutations of the APC and mismatch repair (MMR) genes, respectively [4] [5] [6] . Altogether they are considered to account for about 1% to 5% of all CRCs. Both conditions show a tendency to early onset and to the development of multiple -including extraintestinal -tumors, and are transmitted as highly penetrant autosomal dominant traits. Mutations of the APC and MMR genes are associated with distinctive clinical and molecular phenotypes. FAP is characterized by the development of hundreds to thousands of adenomatous polyps in the large intestine, while HNPCC is associated with the phenomenon of microsatellite instability (MSI) in tumor DNA [7, 8] , which is an expression of impaired MMR function.
About 15%-20% of total CRC patients present with a positive CRC family history [2] , but the majority of these cannot be assigned to any of the known hereditary conditions. The causes of CRC clustering in this 'familial' group are likely heterogeneous, and may include shared environmental factors and/or genetic susceptibility, in addition to chance coincidence. The involvement of genetic factors in the causation of at least a fraction of familial CRCs is demonstrated by different lines of evidence. Mutations of the MMR genes MLH1, MSH2, and MSH6 have been found in a few pedigrees not fulfilling the strict clinical diagnostic criteria for HNPCC [9] [10] [11] [12] [13] [14] [15] [16] . Segregation of a constitutional MMR gene mutation in a familial CRC pedigree is underscored by the finding of MSI in tumor DNA specimens from affected individuals [17] [18] [19] . Further, APC polymorphisms can confer an increased CRC risk in the absence of overt FAP manifestations, the best example being represented by the I1307K variant observed in Ashkenazi Jews, which is associated with an approximately twofold increase in lifetime CRC risk in carriers when compared to the general population [20, 21] . However, such MLH1, MSH2, MSH6, and APC sequence variants are detectable in only a minor fraction of familial CRCs, while studies conducted on longstanding twin registries have shown that about 35% of the CRC burden can be attributed to genetic determinants [22] . Hence, the causes underlying familial CRC aggregation are still poorly understood. In addition, no mutations of the MMR genes have been found in a few documented pedigrees of HNPCC which were not associated with MSI. It is likely that autosomal dominant predisposition in these families is related to mutations in yet unidentified non-MMR genes. The tumor suppressor gene TGFpiIR is a good candidate, but it appears to be only rarely responsible for hereditary CRC, since no further alterations have been reported since the original anedoctal description of a nonsense mutation in a Japanese family [23] .
As a preliminary step towards the clarification of the causes of familial CRC aggregations, we have evaluated clinical characteristics and MSI tumor status in a clinicbased CRC patient population. The results of the study indicate that the vast majority of familial CRCs are not related to gene defects disrupting MMR.
Patients and methods

Patients
The present study involved a series of 100 consecutive patients who underwent surgery for CRC at a single institution (Department of Surgery. 'A. Gemelli' School of Medicine). Patient approval was obtained for family history collection and storage/analysis of tissue samples Data on cancer occurrences were collected on first-degree relatives for all probands. Cancer diagnoses were verified through consultation of medical records. The site of origin of cancer could not be established for two tumors which occurred in first-degree relatives, one gastrointestinal (GI) and one of the female reproductive system Pedigree reconstruction was extended to more distant relatives when at least one cancer occurrence was reported among first-degree relatives
MSI analysis
Specimens of tumor tissue and normal colonic mucosa were collected at the time of surgery and snap-frozen in liquid nitrogen. Tumor samples were examined macroscopically and microscopically prior to DNA extraction to select specimens containing ^ 70% tumor cells. Paired samples of genomic DNA from tumor and normal colonic mucosa of the same patient were PCR-amplified with locus-specific primers in the presence of a-32 P-dCTP. as previously described [12] . After amplification, electrophoresis of PCR products was performed on denaturing urea-polyacrylamide gels, followed by autoradiography. The following microsatellite loci were investigated for MSI status determination: the mononucleotide repeats BAT25, BAT26. and TGFPRII, and the dinucleotide repeats D2S123 and DI7S250. These loci are among the most informative for MSI evaluation, and 4 of them (BAT25, BAT26, D2SI23, and D17S250) are included in the reference panel recommended for MSI evaluation [8] . Instead of the dinucleotide repeat D5S346. we chose to investigate the poly-A repeat located within the coding sequence of the TGFp"RII gene, since insertions/deletions of this mononucleotide are among the most frequent and specific alterations found in MSI CRCs which arise in carriers of MLH1 or MSH2 mutations [24] [25] [26] .
According to suggested guidelines [8] , a sample was defined as microsatellile-unstable (MSI) when allelic shifts were detected at >2 loci in tumor DNA. and microsatellite-stable (MSS) when all tested loci were stable Analysis of further microsatellite sequences, which is indicated when alterations are found at a single locus, was not necessary in this study, since samples could be directly subdivided into MSI or MSS based on analysis of the reference battery of 5 loci.
Results
Overall, 30 of 100 consecutive CRC patients had ^ 1 first-degree relative affected with a malignant tumor. Of the 30 CRC patients with a positive family history, 12 did not have relatives affected with CRC. In 5 of these 12 families there was a record of cancers predominantly related to exposure to environmental agents (lung carcinoma, laryngeal cancer, or hepatocellular carcinoma); 7 additional probands had a family history of gastric cancer (GC) (2 families), prostate, thyroid, or ovarian cancer (1 family each), leukemia and hepatocellular carcinoma (1 family), melanoma and hepatocellular carcinoma (1 family), and breast carcinoma (1 family), respectively. In one pedigree a GI cancer of undetermined origin was reported. Among the 18 probands with a family history of CRC (Table 1) , 3 were diagnosed with a hereditary cancer syndrome (1 classical FAP, 1 attenuated FAP, and 1 LS), based either on the presence of multiple adenomatous polyps or on fulfillment of the Amsterdam diagnostic criteria for HNPCC [27] .
MSI analysis was performed on tumor samples from all probands. Instability of ^2 loci was found in nine tumors. Three of these were from patients who had a positive family history of CRC in first-degree relatives (patients 19, 34, and 93). Patient CRC 93 belonged to a classical HNPCC family, in which segregation of an MLH1 genomic deletion encompassing exon 3 was demonstrated by molecular analysis of leukocyte DNA (data not shown). Although the other two probands with positive CRC family history and MSI tumors did not meet the Amsterdam criteria, a diagnosis of HNPCC could be established after combined evaluation of clinical and molecular data. In fact, patient 19 was the only one affected with CRC in the family, but the location (ascendant colon) and age at diagnosis (36 years), combined with the presence of GC, a tumor often associated with HNPCC, in his mother were suggestive of hereditary GI cancer predisposition. Likewise, the father and brother of patient 34 -who had developed sigmoid colon cancer at 59 years -had been diagnosed with GC and rectal cancer at 70 and 27 years, respectively. MLH1/ MSH2 mutations were searched by both direct sequencing and Southern blotting in patient 19, with negative results.
Of the 6 MSI tumors with negative CRC family history in close relatives, one (patient 78) arose at 45 years, and the remaining five at ages > 63 years. Presence of a maternal grandfather affected with CRC at 47 years, combined with the relatively early age at CRC onset in patient 78, is strongly indicative of an HNPCC diagnosis in this family. The five patients with MSI CRCs, diagnosed at advanced ages, did not have any occurrence of CRC or HNPCC-related tumors even among seconddegree relatives, and can therefore be assigned to the category of sporadic CRCs characterized by hypermethylation of the MLH1 gene promoter and other epigenetic disturbances [28] .
Therefore, 6 hereditary CRC syndromes (2 FAP and 4 HNPCC) could be identified following re-analysis of clinical and family history data in the light of molecular results on MSI testing, leaving a total of 13 MSS CRC patients with a family history of CRC, for which the causes of familial aggregation were not identifiable. Four second primary metachronous or synchronous malignancies were recorded in 3 of the 13 MSS CRC probands ( Table 2 ). The difference in the incidence of second tumors between familial MSS CRCs (4 of 13)
and patients with sporadic CRCs -with the exclusion of patient 78 -(4 of 69) was significant (P = 0.005, with x 2 test). This difference was still significant when familial MSS CRCs were compared with all probands who did not have a diagnosis of FAP or HNPCC and did not have first-degree relatives affected with CRC, since the number of second primary tumors in the latter group was 6 in a total of 81 probands (P = 0.01). The number of tumors in nuclear pedigrees (probands and first-degree relatives) with a hereditary CRC syndrome or a family history of cancer in first-degree relatives divided by site of origin/type is shown in Table 3 . The total number of cancers in the 13 familial MSS CRCs ranged from 2 to 5, with the majority of pedigrees (/; = 6) having 3 cancer occurrences. The total number of CRCs recorded in this group was 2 in 10 nuclear pedigrees, and 3 in the other three families (Table I) . Compared with other familial cancer pedigrees, no extraintestinal site was found to be affected at a significantly high frequency in the MSS familial CRC pedigrees ( Table 3) .
The mean ages of probands at diagnosis of CRC were 50.3 years (range 36-64) in the 6 hereditary CRC families, 62 years (range 44-76) in the 13 familial MSS CRCs, 64.7 years (range 41-83) in the 12 families with history of extraintestinal cancers, and 66.7 in the remaining 69 sporadic patients (range 30-86).
Extension of family history to more distant branches did not identify additional tumors in 7 of the 13 familial 
MSS CRCs. However, verification of cancer diagnoses was largely incomplete for second-degree relatives.
Representative pedigrees of two MSS CRC families, characterized by high tumor density and peculiar tumor clusters, are illustrated in Figure 1 . Out of 105 CRCs which arose in the 100 probands, 32 were in the right colon (cecum, ascendant, and transverse colon, including the splenic flexure) and 73 in the left colon/rectum, distal to the splenic flexure. There was no significant difference in CRC location among HNPCC (right/left: 2/4), FAP (right/left: 1/1), familial MSS (right/left: 5/9), and other cases (right/left: 24/59). However, four out of five MSI sporadic CRCs with advanced age at onset were located in the right colon.
Discussion
The genetic bases of familial CRC clusters have been identified for those conditions showing a clear autosomal dominant pattern of inheritance, namely FAP and HNPCC. However, the causes of CRC aggregation remain elusive for the majority of familial CRCs, for which mendelian segregation is not supported by family history and/or phenotypic characteristics.
MSI status determination is a valuable tool for pinpointing constitutional MMR gene mutations underlying familial CRC aggregates which do not fulfil the diagnostic criteria of a hereditary cancer predisposition syndrome [17] [18] [19] . We have therefore investigated MSI in a series of consecutive CRCs, with the aim of identifying and characterizing subclasses of familial CRC based on combined evaluation of family history, and of clinical and molecular data.
Among the 100 consecutive CRCs which were part of this study, 18 presented with a family history of CRC in first-degree relatives. Following MSI evaluation, a hereditary CRC predisposition syndrome -FAP or HNPCC -could be recognized in five of these pedigrees, as well as in an additional proband who had earlyonset CRC and positive CRC family history limited to a second-degree relative. MSI analysis was instrumental to diagnose HNPCC in three families which did not meet the Amsterdam criteria. Tumors from the other 13 familial CRC probands did not show MSI, and were hence collectively identified as the 'familial MSS CRC subgroup. The existence of familial MSS CRCs has been inferred from previous studies, which were essentially aimed at assessing the combined efficiency of family history, clinical data and tumor MSI analysis for the purpose of HNPCC diagnosis [11, 12, [29] [30] [31] . We found that, in addition to the absence of MSI, this subgroup is characterized by a high incidence of second primary malignancies relative to non-familial CRCs and by a higher mean age at CRC diagnosis compared with hereditary CRC. In fact, age at tumor diagnosis was closer to that observed in the sporadic CRC group.
Several explanations might account for familial aggregation of MSS CRCs. Considering the high prevalence of CRC in the general population, it is to be expected that this tumor may present in two, or occasionally in more than two, first-degree relatives, independently of a strong genetic predisposition. In accordance with this explanation, the number of CRC occurrences among firstdegree relatives was two in the majority of familial MSS CRCs observed in the present study, with a minor proportion showing at most three CRC occurrences. Also, the average age at tumor diagnosis in this group was similar to that recorded in sporadic CRCs, and definitely higher than in hereditary CRC pedigrees. Moreover, some of the extracolorectal cancers observed in MSS CRC families (Table 3) are also commonly found in the general population, indicating that, at least in some cases, their occurrence might represent a sporadic event, unrelated to genetic susceptibility. Therefore, it is likely that a fraction of familial MSS CRCs share the same yet undetermined etiological factors -environmental agents, polygenic inheritance, and/or stochastic events -underlying sporadic CRCs.
On the other hand, the relatively high prevalence of individuals affected with multiple tumors in familial MSS CRCs points towards a major role of genetic predisposition in at least some families. This suggestion is further strengthened by the marked clustering of colorectal and extracolorectal tumors recorded in a few pedigrees, such as those shown in Figure 1 . In family 21, 4 of 5 siblings and their mother from the proband's nuclear family, developed malignancies, all at advanced ages, except for the breast carcinoma diagnosed at 46 years. In family 95, individuals from three consecutive generations presented GI tract malignancies, and the proband developed, in addition to CRC, a synchronous carcinoma of the duodenum, a cancer which is rare in the general population. Assuming that these peculiar cancer aggregations are caused by mutations in one or more predisposing genes, these should be able to influence neoplastic transformation in several tissues, mostly within the GI tract. They should also have a relatively weak effect on colorectal tumorigenesis, compared to wellestablished CRC predisposition syndromes, as suggested by the late age at CRC onset, by the presence of several putative carriers affected with extracolorectal cancers who did not develop CRC, and by the rarity of patients presenting with multiple CRCs (only 1 in the group of familial MSS CRCs).
Since we have investigated a clinic-based population, no inference can be drawn about the prevalence of familial MSS CRCs in the general population. In addition, it is possible that some sporadic patients with MSS tumors might share predisposing genetic factors with the group of familial MSS CRCs. Therefore, the effective prevalence of familial MSS CRC cannot be established in the absence of a molecular marker of this condition. Nevertheless, the results of this study indicate that the majority of familial CRCs not attributable to known CRC genes are MSS. As to the nature of the putative genes involved in familial MSS CRC, the absence of MSI suggests that MMR genes are not implicated in the pathogenesis of these tumors. CRC susceptibility in this group might still be conferred by MMR gene variants causing mild MMR impairment and/or disruption of additional cellular functions not directly related to MMR. The possibility that polymorphisms within MMR or other CRC-predisposing genes, such as APC, SMAD4 [32] , and LKB1/STK11 [33] , are involved in familial MSS CRCs will have to be explored by analyzing larger pedigree series. Likewise, collection and clinical characterization of further families should be helpful for the purpose of genetic counseling, as well as for the identification of novel CRC susceptibility genes.
